Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin)

N/A

Report date: 2026/01/14 16:58:30

Base Information

Drug NameAnti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin)
Drug Alias NameLV20.19 CAR T-Cell therapy (Medical College of Wisconsin)CAR-20/19-T cell therapy (Medical College of Wisconsin)human lentiviral 20.19 (h20.19) CAR T cells therapy (Medical College of Wisconsin)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CD19Anti-CD20
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaCentral Nervous System LymphomaLymphoma, Mantle-Cell +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe Medical College Of Wisconsin Nonprofit
China Registration ClassN/A

Develop Information

Active CompaniesThe Medical College Of Wisconsin Nonprofit
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaCentral Nervous System LymphomaLymphoma, Mantle-Cell +[10] 
Inactive IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A